Wang J, Liu J, Zhou Y, Wang F, Xu K, Kong D
Sci Rep. 2019; 9(1):13177.
PMID: 31511539
PMC: 6739359.
DOI: 10.1038/s41598-019-49123-y.
Mansur A, Roggerio A, Takada J, Caribe P, Avakian S, Strunz C
Sao Paulo Med J. 2016; 134(3):199-204.
PMID: 26786608
PMC: 10496600.
DOI: 10.1590/1516-3180.2015.00650808.
Patounakis G, Bergh E, Forman E, Tao X, Lonczak A, Franasiak J
J Assist Reprod Genet. 2015; 33(1):67-73.
PMID: 26545911
PMC: 4717134.
DOI: 10.1007/s10815-015-0606-z.
Beitelshees A, Voora D, Lewis J
Pharmgenomics Pers Med. 2015; 8:43-61.
PMID: 25897256
PMC: 4397717.
DOI: 10.2147/PGPM.S52900.
Floyd C, Ferro A
Br J Clin Pharmacol. 2013; 77(3):446-57.
PMID: 23834376
PMC: 3952719.
DOI: 10.1111/bcp.12204.
The role of genetics in pre-eclampsia and potential pharmacogenomic interventions.
Williams P, Morgan L
Pharmgenomics Pers Med. 2012; 5:37-51.
PMID: 23226061
PMC: 3513227.
DOI: 10.2147/PGPM.S23141.
Pharmacogenetics of cardiovascular drug therapy.
Peters B, Klungel O, de Boer A, Stricker B, der Zee A
Clin Cases Miner Bone Metab. 2012; 6(1):55-65.
PMID: 22461099
PMC: 2781215.
Genomics and the efficacy of aspirin in the treatment of cerebrovascular disease.
Cavallari L, Momary K
Curr Treat Options Cardiovasc Med. 2009; 11(3):191-200.
PMID: 19433014
DOI: 10.1007/s11936-009-0020-x.
Pharmacogenetics of aspirin resistance: a comprehensive systematic review.
Goodman T, Ferro A, Sharma P
Br J Clin Pharmacol. 2008; 66(2):222-32.
PMID: 18429969
PMC: 2492913.
DOI: 10.1111/j.1365-2125.2008.03183.x.
Increased activity of phosphatase PP2A in the presence of the PlA2 polymorphism of alphaIIbbeta3.
Wang H, Yan B, Satterwhite L, Ma Q, Goldschmidt-Clermont P
Biochem Biophys Res Commun. 2007; 367(1):72-7.
PMID: 18155662
PMC: 2275810.
DOI: 10.1016/j.bbrc.2007.12.094.
Does glycoprotein IIIa gene (Pl(A)) polymorphism influence clopidogrel resistance? : a study in older patients.
Papp E, Havasi V, Bene J, Komlosi K, Talian G, Feher G
Drugs Aging. 2007; 24(4):345-50.
PMID: 17432927
DOI: 10.2165/00002512-200724040-00006.
Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions.
Undas A, Brummel-Ziedins K, Mann K
Blood. 2006; 109(6):2285-92.
PMID: 17148593
PMC: 1852201.
DOI: 10.1182/blood-2006-01-010645.
Implications of pharmacogenetics for individualizing drug treatment and for study design.
Meisel C, Gerloff T, Kirchheiner J, Mrozikiewicz P, Niewinski P, Brockmoller J
J Mol Med (Berl). 2003; 81(3):154-67.
PMID: 12682724
DOI: 10.1007/s00109-002-0417-4.
Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics.
Goldschmidt-Clermont P, Roos C, Cooke G
J Thromb Thrombolysis. 1999; 8(2):89-103.
PMID: 10436139
DOI: 10.1023/a:1008954916972.
